Dr. Nicholas Fidelman, MD

Dr. Fidelman practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Fidelman's NPI, 1548387764, was assigned on March 23, 2007. Dr. Fidelman graduated from UCSF School of Medicine in 2002. Dr. Fidelman holds California license A84789.

Dr. Fidelman's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Fidelman's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Fidelman to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fidelman practices, 2 sites in all. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Fidelman's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Fidelman is board certified in interventional radiology and diagnostic radiology by the American Board of Radiology. Dr. Fidelman is licensed in California.

CMS data shows 877 Medicare services from Dr. Fidelman across 22 procedure codes in 2024, for 347 Medicare patients. Medicare paid $66,682 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 347 Medicare patients who saw Dr. Fidelman in 2024. The largest group is 65 to 74, with 161 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 38% are also on Medicaid. Their average risk score is 3.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fidelman's median patient age at 66, with 49% women.

In 2024, Dr. Fidelman wrote 21 Medicare Part D claims. 86% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $253 in total drug cost. In 2017, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Fidelman for performance year 2024, reported individually. Dr. Fidelman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fidelman as offering telehealth.

Dmand AI links 68 papers to Dr. Fidelman, published from 2008 to 2024. 2021 was the busiest year, with 5. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Chemoembolization, Therapeutic. Dr. Fidelman has published most often in J Vasc Interv Radiol. Dr. Fidelman's most frequent co-authors are Robert K. Kerlan, MD, Jeanne M. Laberge, MD and Maureen Pearl Kohi, MD.

Dmand AI links Dr. Fidelman to 6 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Hepatocellular, Liver Neoplasms and Cholangiocarcinoma. University of California, San Francisco sponsors the most, 3.

CMS Open Payments shows 84 general payments to Dr. Fidelman from 16 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 45% of the total. Guerbet LLC paid the most, $7,528.

Dr. Fidelman graduated from UCSF School of Medicine in 2002. Dr. Fidelman is a member of SIR.

Dr. Fidelman is in network with 5 carriers, including United Healthcare, Blue Cross and Blue Shield of Kansas City and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.